Cytokinetics, Inc. (CYTK), a biopharmaceutical company focused on muscle biology, on Monday announced the launch of the AMBER-HFpEF ...

Cytokinetics (CYTK) announced that AMBER-HFpEF is open to enrollment. AMBER-HFpEF is a Phase 2 randomized, placebo-controlled, double-blind, ...

$10,000 of CYTOKINETICS INC. lobbying was just disclosed, from Q4 of 2024, in a new Lobbying Disclosure Act filing. This included lobbying on issues like: "General healthcare representation.

Cytokinetics has been a top biotech takeover candidate for some time, thanks to blockbuster speculation about its lead drug aficamten, but a $1 billion-plus set of financing deals shows it is ...

Cytokinetics' hopes of resurrecting cardiac myosin activator omecamtiv mecarbil have suffered another setback, after the drug failed to show a benefit in a phase 3 heart failure study.

RBC Capital Mkts has recently initiated Cytokinetics, Inc. (CYTK) stock to Outperform rating, as announced on November 8, 2024, according to Finviz. Earlier, on August 13, 2024, Goldman had reduced ...

Edgewise Therapeutics (NASDAQ: EWTX) is a small-cap pharmaceutical stock that has been all the rage recently. Shares are up 55% in the last three months and up 332% over the past 52 weeks.

After hours: January 17 at 6:11:16 PM EST ...

Kiunga Hospital received a timely lifeline on New Year’s Day, in response to an urgent appeal from the Western Provincial Health Authority (WPHA).